Reynders McVeigh Capital Management’s Novo Nordisk NVO Stock Holding History

Reynders McVeigh Capital Management’s Portfolio NVO Stock Details NVO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-274,101	Closed	-$13.9M	–	203
2025 Q4	$13.9M	Sell	274,101 -68,033	-20%	-$3.48M	0.65%	42
2025 Q3	$19M	Sell	342,134 -21,755	-6%	-$1.27M	0.89%	38
2025 Q2	$25.1M	Buy	+363,889	New	+$24.8M	1.25%	31
2024 Q2	–	Sell	-448,673	Closed	-$57.6M	–	202
2024 Q1	$57.6M	Sell	448,673 -433	-0.1%	-$51.5K	3.32%	5
2023 Q4	$46.5M	Sell	449,106 -40,118	-8%	-$3.97M	2.94%	9
2023 Q3	$44.5M	Sell	489,224 -19,100	-4%	-$1.68M	3.06%	9
2023 Q2	$41.1M	Sell	508,324 -39,672	-7%	-$3.24M	2.7%	11
2023 Q1	$43.6M	Sell	547,996 -33,608	-6%	-$2.38M	3%	10
2022 Q4	$39.4M	Buy	581,604 +4,736	+0.8%	+$278K	2.89%	11
2022 Q3	$28.7M	Buy	576,868 +33,462	+6%	+$1.79M	2.23%	15
2022 Q2	$30.3M	Buy	543,406 +9,874	+2%	+$548K	2.27%	14
2022 Q1	$29.6M	Buy	533,532 +36,664	+7%	+$1.88M	1.81%	21
2021 Q4	$27.8M	Buy	496,868 +34,958	+8%	+$1.89M	1.58%	24
2021 Q3	$22.2M	Buy	461,910 +21,268	+5%	+$1.03M	1.36%	28
2021 Q2	$18.5M	Buy	440,642 +37,330	+9%	+$1.45M	1.13%	32
2021 Q1	$13.6M	Buy	403,312 +45,204	+13%	+$1.61M	0.91%	38
2020 Q4	$12.5M	Buy	358,108 +19,542	+6%	+$675K	0.85%	38
2020 Q3	$11.8M	Buy	338,566 +50,006	+17%	+$1.67M	0.91%	36
2020 Q2	$9.45M	Buy	288,560 +54,098	+23%	+$1.73M	0.83%	35
2020 Q1	$7.06M	Buy	234,462 +42,850	+22%	+$1.28M	0.8%	35
2019 Q4	$5.54M	Buy	191,612 +23,830	+14%	+$660K	0.53%	40
2019 Q3	$4.34M	Buy	167,782 +20,290	+14%	+$513K	0.46%	43
2019 Q2	$3.76M	Buy	147,492 +51,850	+54%	+$1.28M	0.4%	48
2019 Q1	$2.5M	Buy	95,642 +17,560	+22%	+$432K	0.28%	62
2018 Q4	$1.8M	Sell	78,082 -16,794	-18%	-$373K	0.24%	70
2018 Q3	$2.24M	Sell	94,876 -11,008	-10%	-$269K	0.26%	66
2018 Q2	$2.44M	Sell	105,884 -9,236	-8%	-$220K	0.31%	60
2018 Q1	$2.83M	Sell	115,120 -24,764	-18%	-$650K	0.36%	52
2017 Q4	$3.75M	Sell	139,884 -30,214	-18%	-$768K	0.49%	43
2017 Q3	$4.09M	Sell	170,098 -24,730	-13%	-$559K	0.53%	39
2017 Q2	$4.18M	Sell	194,828 -8,558	-4%	-$173K	0.56%	42
2017 Q1	$3.49M	Sell	203,386 -7,016	-3%	-$122K	0.48%	47
2016 Q4	$3.77M	Buy	210,402 +131,378	+166%	+$2.38M	0.54%	44
2016 Q3	$1.64M	Sell	79,024 -2,200	-3%	-$54.5K	0.24%	76
2016 Q2	$2.18M	Buy	81,224 +4,900	+6%	+$134K	0.32%	61
2016 Q1	$2.07M	Buy	76,324 +18,826	+33%	+$504K	0.31%	65
2015 Q4	$1.67M	Sell	57,498 -1,400	-2%	-$38.8K	0.27%	63
2015 Q3	$1.6M	Sell	58,898 -4,400	-7%	-$125K	0.28%	61
2015 Q2	$1.73M	Buy	63,298 +5,550	+10%	+$156K	0.28%	59
2015 Q1	$1.54M	Buy	57,748 +1,560	+3%	+$35.9K	0.26%	64
2014 Q4	$1.19M	Buy	56,188 +250	+0.4%	+$5.58K	0.21%	79
2014 Q3	$1.33M	Sell	55,938 -2,178	-4%	-$50.1K	0.25%	66
2014 Q2	$1.34M	Sell	58,116 -18,564	-24%	-$410K	0.31%	64
2014 Q1	$1.75M	Sell	76,680 -1,140	-1%	-$24.3K	0.41%	52
2013 Q4	$1.44M	Sell	77,820 -5,550	-7%	-$96.7K	0.36%	58
2013 Q3	$1.41M	Sell	83,370 -2,080	-2%	-$35K	0.39%	57
2013 Q2	$1.32M	Buy	+85,450	New	+$1.42M	0.39%	56

Other funds holding NVO

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

DAM

Diamant Asset Management Ridgefield, Connecticut $147M AUM 25.76% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Folketrygdfondet Oslo Norway, Norway $5.64B AUM 47.16% 1-Year Est. Return

Reynders McVeigh Capital Management's NVO Position: Q1 2026 in Review

Reynders McVeigh Capital Management sold out of Novo Nordisk (NVO) in Q1 2026, closing a stake of 274,101 shares — an estimated $13.9M sold.

Reynders McVeigh Capital Management first reported a position in NVO in Q2 2013 and held it in 47 quarters. The position peaked at $57.6M in Q1 2024. 1,276 funds tracked by Wall St. Rank hold NVO as of Q1 2026.

Reynders McVeigh Capital Management reported no remaining Novo Nordisk position as of Q1 2026 after selling out during the quarter.
Reynders McVeigh Capital Management sold 274,101 Novo Nordisk shares in Q1 2026, an estimated $13.9M.
Reynders McVeigh Capital Management first reported a position in Novo Nordisk in Q2 2013 and held it in 47 quarters.
Reynders McVeigh Capital Management's Novo Nordisk position peaked at $57.6M in Q1 2024.
1,276 funds tracked by Wall St. Rank held Novo Nordisk as of Q1 2026.

Based on Reynders McVeigh Capital Management's 13F filing for Q1 2026, filed 27 Apr 2026.